This article is more than 5 years old. Information may no longer be current.
FDA approves Keytruda for advanced urothelial carcinoma
Click Here to Manage Email Alerts
The FDA granted accelerated and regular approval to pembrolizumab for the first- and second-line treatments of locally advanced or metastatic urothelial carcinoma, according to the drug’s manufacturer.
Regular approval for the second-line indication included data from the multicenter, randomized, active-controlled KEYNOTE-045 trial, designed to evaluate pembrolizumab (Keytruda, Merck) — an anti–PD-1 monoclonal antibody — in patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Patients in that trial received 200 mg pembrolizumab every 3 weeks (n = 270) or investigator’s choice of a chemotherapy regimen — which included paclitaxel, docetaxel or vinflunine — every 3 weeks (n = 272).
Patients in the pembrolizumab arm demonstrated longer median OS (10.3 vs. 7.4 months; HR = 0.73; 95% CI, 0.59-0.91) and a higher objective response rate (21% vs. 11%; P = .002) compared with patients in the chemotherapy arm.
Researchers observed no statistically significant difference in PFS between the arms.
Accelerated approval for the first-line indication included data from the single-arm, open-label KEYNOTE-052 trial, designed to evaluate 200 mg pembrolizumab every 3 weeks in 370 patients with locally advanced or metastatic urothelial carcinoma deemed not eligible for cisplatin-containing chemotherapy (median follow-up, 7.8 months).
Patients demonstrated an ORR of 28.6% (95% CI, 24-34); however, median duration of response had not been reached (range, 1.4+ months to 7.8+ months).
The most common adverse events in both trials included fatigue, musculoskeletal pain, pruritus, decreased appetite, nausea, diarrhea, constipation and rash. Immune-mediated adverse reactions included pneumonitis, colitis, hepatitis and endocrinopathies.
Discontinued treatment secondary to adverse reactions occurred in 8% of patients in the KEYNOTE-045 trial and in 11% in the KEYNOTE-052 trial.
Dose interruption occurred in approximately 20% of patients in each trial.
The FDA recommended a dose and schedule of 200 mg pembrolizumab as an IV infusion over 30 minutes every 3 weeks for the treatment of urothelial carcinoma.
Pembrolizumab also is approved for treatment of unresectable or metastatic melanoma; first-line treatment of patients with metastatic non–small cell lung cancer whose tumors have high PD-L1 expression but do not have EGFR or ALK genomic tumor aberrations; patients with metastatic, PD-L1–expressing NSCLC that progressed on or after platinum-containing chemotherapy; and patients with recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-containing chemotherapy.